Ophiomics
Ophiomics is a clinical-stage medtech company focused on precision liver medicine, developing AI and genomics-powered diagnostic products for diagnosis, prognosis, treatment selection, and follow-up of liver diseases. Founded in 2015, the company has developed a modular lab platform for rapid development of genomic tests, supporting both liquid and tissue biopsies. Their products are designed to integrate seamlessly into clinical practice, offering actionable insights for clinicians. Ophiomics has achieved ISO 13485 and ISO 9001 certifications and has launched its first product, HepatoPredict, with next-generation tests for early liver cancer detection in validation. Their mission is to empower healthcare professionals with precise, transparent, and trustworthy AI-powered algorithms and omics-based diagnostics to improve outcomes for patients with liver disease.
Ophiomics
Ophiomics is a clinical-stage medtech company focused on precision liver medicine, developing AI and genomics-powered diagnostic products for diagnosis, prognosis, treatment selection, and follow-up of liver diseases. Founded in 2015, the company has developed a modular lab platform for rapid development of genomic tests, supporting both liquid and tissue biopsies. Their products are designed to integrate seamlessly into clinical practice, offering actionable insights for clinicians. Ophiomics has achieved ISO 13485 and ISO 9001 certifications and has launched its first product, HepatoPredict, with next-generation tests for early liver cancer detection in validation. Their mission is to empower healthcare professionals with precise, transparent, and trustworthy AI-powered algorithms and omics-based diagnostics to improve outcomes for patients with liver disease.
TL;DR
Stage: Clinical-stage medtech
Focus: AI- and genomics-powered precision liver diagnostics (HepatoPredict)
Founded: 2015 (Lisbon, Portugal)
Certifications: ISO 13485, ISO 9001
Recent financing: Series A led by BlueCrow Capital (Jan 18, 2023)
Company Overview
Problem Domain
Precision liver medicine — diagnosis, prognosis, treatment selection, and monitoring for liver diseases including liver cancer.
Founded
2015
Industry
Biotechnology
Tech Stack
Funding Track Record
€1,000,000
Seed equity complementary to an EIC Accelerator grant
Series A announced to support commercialization of HepatoPredict
Investor Signal
“Includes European public innovation funding (European Innovation Council / EIC Fund, EASME) and VC lead investor BlueCrow Capital”